Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited neurodegenerative disease caused by expansion of a glutamine-encoding repeat in ataxin 1 (ATXN1). In all known polyglutamine diseases, the glutamine expansion confers toxic functions onto the protein; however, the mechanism by which this occurs remains enigmatic, in light of the fact that the mutant protein apparently maintains interactions with its usual partners. Here we show that the expanded polyglutamine tract differentially affects the function of the host protein in the context of different endogenous protein complexes. Polyglutamine expansion in ATXN1 favours the formation of a particular protein complex containing RBM17, contributing to SCA1 neuropathology by means of a gain-of-function mechanism. Concomitantly, polyglutamine expansion attenuates the formation and function of another protein complex containing ATXN1 and capicua, contributing to SCA1 through a partial loss-of-function mechanism. This model provides mechanistic insight into the molecular pathogenesis of SCA1 as well as other polyglutamine diseases.
Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited neurodegenerative disease caused by expansion of a glutamine-encoding repeat in ataxin 1 (ATXN1). In all known polyglutamine diseases, the glutamine expansion confers toxic functions onto the protein; however, the mechanism by which this occurs remains enigmatic, in light of the fact that the mutant protein apparently maintains interactions with its usual partners. Here we show that the expanded polyglutamine tract differentially affects the function of the host protein in the context of different endogenous protein complexes. Polyglutamine expansion in ATXN1 favours the formation of a particular protein complex containing RBM17, contributing to SCA1 neuropathology by means of a gain-of-function mechanism. Concomitantly, polyglutamine expansion attenuates the formation and function of another protein complex containing ATXN1 and capicua, contributing to SCA1 through a partial loss-of-function mechanism. This model provides mechanistic insight into the molecular pathogenesis of SCA1 as well as other polyglutamine diseases.
Expansion of an unstable translated CAG repeat located in different disease genes has so far been identified as causing nine dominantly inherited neurodegenerative disorders, the so-called polyglutamine diseases: Huntington's disease, spinobulbar muscular atrophy, dentatorubropallidoluysian atrophy, and six autosomal-dominant spinocerebellar ataxias 1 . As would be expected for dominant mutations, polyglutamine expansions confer toxic properties on the host proteins [1] [2] [3] ; animal models genetically lacking the polyglutaminecontaining proteins do not develop neurodegeneration [4] [5] [6] [7] . However, expansion of the polyglutamine tract is necessary, but not sufficient, to cause pathology: in the case of SCA1, for example, expanded ataxin 1 (ATXN1) does not produce cerebellar degeneration if it lacks the nuclear localization signal 8 or the AXH (ATXN1-HBP1) domain 9 , or if a serine to alanine substitution prevents phosphorylation at residue 776 (ref. 10) . These and other studies in spinobulbar muscular atrophy and Huntington's disease indicate that protein domains outside of the polyglutamine tract have an important role in the selective neurotoxicity observed in these diseases [11] [12] [13] [14] [15] [16] [17] [18] . Moreover, they suggest that there is a relationship between the normal functions of the wild-type proteins and the toxic functions of their expanded counterparts. Given that mouse and fly models overexpressing wild-type ATXN1 develop a mild version of SCA1 (ref. 19 ) begs the question of whether the glutamine expansion enhances some interactions to mediate the gain of function.
In an effort to address this question, we sought to characterize protein partners of ATXN1 that interact with it in a manner dependent on two criteria necessary for toxicity: polyglutamine expansion and phosphorylation at serine 776 (S776). We have identified RBM17 (RNA-binding motif protein 17) as a protein that meets these criteria. Here we show that ATXN1 forms at least two distinct, large native complexes, one containing capicua (CIC) and the other containing RBM17. Polyglutamine expansion alters the proportion of the mutant protein participating in the formation of these complexes in vivo. Furthermore, we show that the ATXN1-RBM17 complex causes disease by a gain-of-function mechanism, whereas the ATXN1-CIC complex causes a loss of function. These data not only show that there is an unexpected loss of function that contributes to SCA1 pathology, but provide a molecular mechanism to explain how glutamine expansion causes both gain and loss of function.
RBM17 preferentially interacts with glutamine-expanded ATXN1
To identify proteins that preferentially interact with ATXN1 in a manner dependent on both polyglutamine expansion and S776 phosphorylation, we performed a yeast two-hybrid screen 20 using several human ATXN1 constructs with either wild-type (30Q) or expanded (82Q) polyglutamine tracts and varying phosphorylation status at S776 (wild-type (S776), phosphorylation-defective (S776A), or phosphorylation-mimicked (S776D)) (Fig. 1a) . This screen yielded a protein called RBM17 that binds specifically to ATXN1(S776D) (Fig. 1b) . We verified the ATXN1-RBM17 interaction in mammalian cells by co-affinity purification assays using lysates from HEK293T cells transfected with glutathione S-transferase (GST)-tagged ATXN1 and Myc-tagged RBM17 (Fig. 1c, arrow) . We also performed coimmunoprecipitation assays on mouse cerebellar extracts using a specific RBM17 antibody ( Supplementary Fig. 1 ). The anti-RBM17 antibody co-immunoprecipitated Atxn1 from cerebellar extracts (Fig. 1d, arrow) , suggesting that wild-type ATXN1 and RBM17 do indeed interact in vivo.
To determine whether the interaction between RBM17 and ATXN1 depends on phosphorylation of S776 of ATXN1 in mammalian cells, we transfected Myc-RBM17 with GST-ATXN1(S776), GST-ATXN1(S776A), or GST-ATXN1(S776D) into HEK293T cells. Both wild-type ATXN1 and ATXN1(S776D) were able to precipitate RBM17, but ATXN1(S776A) showed almost no interaction with RBM17 (Fig. 2a , arrow, and Supplementary Fig. 2 ), indicating that the interaction of RBM17 with ATXN1 requires S776 phosphorylation. That RBM17 interacts more robustly with ATXN1(S776D) than with ATXN1(S776) suggests that S776 phosphorylation is important for the interaction. We next determined the domains responsible for the interaction between the two proteins using a series of ATXN1 and RBM17 deletion constructs. We found that the carboxy-terminal region of RBM17 interacts with the C-terminal sequence of ATXN1 harbouring the phosphorylated S776 residue (Supplementary Fig. 3) .
To test the effect of polyglutamine tract length on the ATXN1-RBM17 interaction, we performed co-affinity purification assays by transfecting HEK293T cells with GST-fused ATXN1 containing 2Q, 30Q or 82Q. The interaction between Myc-RBM17 and GST-ATXN1 was strongly enhanced by expansion of the polyglutamine tract ( Fig. 2b , arrow; see also Supplementary Fig. 4 ). We checked the phosphorylation level of S776 in ATXN1 containing a different polyglutamine tract length and found little if any enhancement in S776 phosphorylation of ATXN1 by polyglutamine expansion (Fig. 2b , bracket; see also Supplementary Fig. 5 ). These data suggest that expansion of the amino-terminal polyglutamine tract of ATXN1 alters the conformation of the C-terminal regions of the protein, making it more accessible to RBM17 binding.
We explored Rbm17 expression patterns in mouse brain and found Rbm17 protein abundant in Purkinje cell nuclei in wild-type mouse cerebella (Fig. 2c) , consistent with the mRNA expression pattern shown in the Allen Brain Atlas 21 . We also tested Rbm17 expression in SCA1 transgenic mice (B05 line) 22 , which express a polyglutamine-expanded form of human ATXN1 (ATXN1(82Q)) in Purkinje cells. Rbm17 expression remained high in the Purkinje cells of 18-week-old B05 mice, at a time when there is marked Purkinje cell atrophy ( Fig. 2d and Supplementary Fig. 6 ), suggesting that Rbm17 is not depleted in SCA1.
To ascertain the relevance of the ATXN1-RBM17 interaction to ATXN1-induced neuropathology in vivo, we used a Drosophila model of SCA1 in which expression of polyglutamine-expanded human ATXN1 in the Drosophila eye causes retinal degeneration, ommatidial disorganization and fusion, and interommatidial bristle loss 19 . We established the physical interaction between ATXN1 and Drosophila RBM17 (dRBM17) (data not shown) and looked for genetic interaction between the two proteins by crossing SCA1 flies with dRBM17 mutant flies ( Fig. 3 and Supplementary Fig. 7) . A heterozygous loss of one dRBM17 allele partially suppressed ommatidial disorganization phenotypes of SCA1 flies at 30 uC (Fig. 3b) , a temperature at which ATXN1(82Q) causes severe retinal degeneration (Fig. 3a) . To verify the specificity of the genetic interaction, we generated two different lines of transgenic flies that expressed either human RBM17 (hRBM17) or dRBM17. Overexpression of either hRBM17 or dRBM17 alone in the Drosophila eye did not cause any obvious external morphological phenotypes at 25 uC (Supplementary Fig. 7 ). Co-expression of hRBM17 (or dRBM17) with ATXN1(82Q) worsened ommatidial disorganization and bristle loss in SCA1 flies (Fig. 3c, d ). In contrast, hRBM17 (or dRBM17) had little effect when co-expressed with wild-type ATXN1(30Q) ( GFP:
GST pull down phosphorylation and polyglutamine tract expansion. a, Wild-type ATXN1 and ATXN1(S776D), but not ATXN1(S776A), interacted with RBM17. b, RBM17 bound most strongly to polyglutamine-expanded ATXN1. The bracket highlights that there is no obvious difference in S776 phosphorylation depending on polyglutamine expansion in ATXN1 when using a PN1168 antibody (specific to phosphorylated S776 of ATXN1) for immunoblotting. c, d, Rbm17 expression in the nuclei of Purkinje cells of 18-week-old mice from either wild type (FVB) (c) or SCA1 transgenic (ATXN1(82Q)) homozygotes (d). Rbm17 protein (green) was co-immunostained with calbindin (red, Purkinje cell marker) and Toto3 (blue, nuclear marker). f). These genetic data suggest that RBM17 has a crucial role in mediating the toxicity of polyglutamine-expanded ATXN1 in vivo.
Native ATXN1 complexes contain RBM17
We next asked whether the ATXN1-RBM17 interaction is transient or whether the two proteins form a stable protein complex in vivo. We first analysed the elution profile of Rbm17 in wild-type mouse cerebellum using gel-filtration chromatography and compared it with the elution profile of Atxn1. Rbm17 eluted in a broad range of fractions (8 through 17) with at least two identifiable peaks (Fig. 4a , red and blue boxes): one peak coincided with large protein complexes with an estimated size larger than 4 MDa, at fraction 9, and a second peak occurred at fractions 12-13, consistent with small protein complexes at ,700 kDa in size. The elution profile of RBM17 in a human cell line, HEK293T cells, also revealed two elution peaks enriched for this protein in fractions similar to those found in wild-type mouse cerebellum, but relatively more RBM17 protein eluted in the large protein complexes detected in fraction 9 ( Supplementary Fig. 8a , red and blue boxes). ATXN1 also eluted in a broad range of fractions and was associated with two isoforms of CIC ( Fig. 4a and Supplementary  Fig. 8a , top two rows), consistent with our previous work 23 . Given that the proteins showed broadly overlapping elution profiles, we sought to establish the fractions in which ATXN1 and RBM17 interact. We transfected HEK293T cells with Flag-tagged ATXN1(82Q), fractionated cell extracts, and immunoprecipitated Flag-ATXN1(82Q) from each of the fractions using anti-Flag antibody ( Supplementary Fig. 8b ). We found that ATXN1(82Q) immunoprecipitated endogenous RBM17 proteins from the large protein complexes (peak fraction 9, red box at the bottom panel), but not from the small protein complexes (peak fractions 12-13, blue box at the bottom panel). This suggests that ATXN1 and RBM17 interact in the large protein complexes. Incorporation of RBM17 and ATXN1 into large protein complexes was not caused by differential phosphorylation of ATXN1 at S776 (Supplementary Fig. 9 ). Of note, Atxn1 was not required for the presence of Rbm17 in the large protein complexes, as Rbm17 was still present in fractions 8-10 in Atxn1 knockout (Atxn1 2/2 ) mouse cerebellum (Supplementary Fig.  10 ). This suggests that Rbm17 associates with other factors in the large protein complex in addition to forming complexes with Atxn1.
Glutamine expansion increases RBM17 in ATXN1 complexes
The findings that polyglutamine expansion enhanced the interaction of ATXN1 with RBM17 ( Fig. 2b and Supplementary Fig. 4 ) and that ATXN1-RBM17 associated in vivo into large protein complexes ( Supplementary Fig. 8b ) suggested to us that more RBM17 molecules might incorporate into the large protein complexes in the presence of polyglutamine-expanded ATXN1. To test this hypothesis, we examined the elution profile of Rbm17 in cerebellar protein extracts from SCA1 knock-in mice that carry the polyglutamine-expanded (Atxn1(154Q)) allele 24 ( Fig. 4b ). Rbm17 from SCA1 knock-in mouse cerebellar extracts fractionated into both large (Fig. 4b , red box) and small (Fig. 4b , blue box) protein complexes, but the relative ratio of Rbm17 incorporation into the large protein complexes was much greater in the SCA1 knock-in mice than in wild-type mice (Fig. 4) . These data strongly support the hypothesis that more RBM17 is incorporated into large protein complexes because of enhanced interaction with polyglutamine-expanded ATXN1.
Two distinct large ATXN1 protein complexes A major portion of wild-type Atxn1 co-elutes and forms large native protein complexes with two isoforms of Cic in mouse cerebellum 23 ( Fig. 4a, top two rows) . We therefore asked whether in vivo native protein complexes containing ATXN1-CIC contain RBM17 as well. Interestingly, despite the fact that both RBM17 and CIC interact with ATXN1, the two proteins were not detectable in the same ATXN1 (Figs 1d and 5a ) or in HEK293T cells (Supplementary Fig. 11 ). This suggests that there are at least two different ATXN1-associated large protein complexes in vivo: one containing ATXN1 and RBM17, the other containing ATXN1 and CIC. Interestingly, these two proteins, and possibly the protein complexes associated with them, have contrary effects on SCA1 pathology: extra RBM17 augments expanded ATXN1 toxicity in Drosophila (Fig. 3) , but extra CIC represses it 23 . Consistent with these results as well as the accumulating evidence that nuclear inclusions serve a protective role in SCA1-affected cells 25 , we observed that CIC enhanced, whereas RBM17 slightly suppressed, ATXN1 nuclear inclusion formation (Supplementary Fig. 12 ). Overexpression of Atxn1-like (a paralogue of Atxn1), which can interact with Atxn1 and Cic, also increases sequestration of mutant Atxn1 into inclusions in Purkinje cell nuclei of SCA1 knock-in mice 25 . The identification of two biochemically and functionally distinct large ATXN1 protein complexes led us to test whether RBM17 and CIC compete for interaction with ATXN1. We found in Neuro-2a as well as in HEK293T cells that RBM17 and CIC do indeed compete for ATXN1 interaction (Fig. 5b and Supplementary Fig. S11 ). These data, along with results described above, indicate that there are at least two distinct endogenous protein complexes associated with ATXN1.
GMR>SCA1(82Q), UAS-GFP GMR>SCA1(82Q), UAS-hRBM17

GMR>SCA1(30Q), UAS-GFP GMR>SCA1(30Q), UAS-hRBM17
SCA1 involves gain and partial loss of ATXN1 function
Next, we wished to address the question of how the RBM17-and CIC-containing endogenous protein complexes affect each other's formation and function, and how their interactions influence SCA1 neuropathology. Given that ATXN1-RBM17 interactions are polyglutamine-length-dependent and that RBM17 and CIC can compete with each other to form distinct ATXN1-containing protein complexes, we infer that polyglutamine expansion in ATXN1 favours the formation of the RBM17-containing protein complex, leaving mostly the wild-type ATXN1 to form a CIC-containing protein complex. Bearing in mind that the expression level of wild-type ATXN1 in SCA1 knock-in mice and in human patients is reduced to half the levels in healthy controls, and that Cic expression is also significantly reduced in SCA1 knock-in (Atxn1 154Q/1 ) mice (Supplementary Fig.  13 ), formation of expanded ATXN1-RBM17-containing complexes in soluble fractions is increased but the formation of wild-type ATXN1-CIC-containing protein complexes is decreased (Fig. 4) . These considerations raise the interesting possibility that SCA1 is caused not only by a toxic gain-of-function mechanism but also by a partial loss of wild-type ATXN1 function.
To ascertain whether SCA1 neuropathology is affected by the presence or absence of the wild-type Atxn1 protein, we crossed Atxn1 heterozygote (Atxn1
) animals with the SCA1 knock-in (Atxn1
154Q/2 mice showed a worsened performance on the rotarod than Atxn1 154Q/1 animals (Fig. 6a) . Furthermore, Atxn1 154Q/2 mice had a shortened lifespan compared with Atxn1 154Q/1 animals (Fig. 6b) . Given that Atxn1 heterozygotes (Atxn1 154Q/-animals showed a worsened rotarod performance (asterisk, P , 0.05; double asterisk, P , 0.005) and earlier lethality (P , 1 3 10 26 ) than Atxn1 154Q/1 mice. Error bar is the standard error of the mean (s.e.m.). c, Model for SCA1 neuropathology. In wild-type individuals, there are at least two distinct and mutually exclusive ATXN1-associated endogenous protein complexes in vivo. The formation of one of these complexes (ATXN1-RBM17) seems to be regulated in that it requires phosphorylation of ATXN1. Polyglutamine expansion in ATXN1 favours formation of the RBM17-containing complex, thereby enhancing one endogenous function and contributing to neuropathology by means of a gain-of-function mechanism. Polyglutamine expansion concomitantly decreases the formation of CIC-containing complex, resulting in a partial loss of function. strongly suggest that wild-type Atxn1 and its interacting proteins are protective and that loss of the wild-type Atxn1 worsens SCA1 neuropathology.
Discussion
The results presented in this study provide a mechanistic explanation of how polyglutamine expansion can cause both gain and loss of normal protein function: the expansion differentially affects the interactions of the host protein in the context of distinct endogenous protein complexes in vivo. Previous work showed that polyglutamine-expanded ATXN1, like its wild-type counterpart, interacts with several nuclear proteins and incorporates into native complexes 23 . Some complexes, like those containing CIC, are relatively stable, whereas ATXN1's interactions with GFI-1 and TIP60-RORa are more transient 9, 23, 26 . RBM17 is unique among these factors, however, in that it is the only protein discovered so far whose interaction with ATXN1 is regulated by the length of the latter's polyglutamine tract and phosphorylation status at S776, two features that are absolute requirements for SCA1 pathogenesis.
Previously we have shown that wild-type and polyglutamineexpanded ATXN1 associate into large and small protein complexes (Fig. 4b, second row) and that incorporation of polyglutamineexpanded ATXN1 into the large complexes causes SCA1 neuropathology 23, 25 . In this study, we found that there are at least two distinct large native protein complexes associated with ATXN1: one containing CIC and the other RBM17. Polyglutamine expansion in ATXN1 strongly enhanced the formation of an ATXN1-RBM17-containing protein complex in both cell culture and in SCA1 knock-in mouse cerebellum, providing a mechanistic explanation for the toxic gain of function. RBM17 is expressed in the nuclei of a broad range of neuronal and non-neuronal tissues 21, 27 . It is interesting that both RBM17 (refs 28, 29) and ATXN1 (ref. 30) seem to be involved in regulation of RNA metabolism. One potential molecular function of this protein complex might thus be RNA splicing. This hypothesis receives some support from the observation that ATXN1 and RBM17 incorporation into large protein complexes was strongly decreased after RNase treatment ( Supplementary Fig. 14) .
Mice lacking wild-type Atxn1 but carrying polyglutamineexpanded Atxn1 suffered more severe disease and greater lethality, suggesting that either wild-type Atxn1 protects against the mutant protein or is essential for neuronal integrity. It is noteworthy that Atxn1 null mice do not develop SCA1 features 4 and that polyglutamine-expanded ATXN1 does not differentially interact with wildtype ATXN1 (Supplementary Fig. 15 ), arguing against loss of function or dominant-negative mechanisms. Our data suggest that wild-type ATXN1 competes with polyglutamine-expanded ATXN1 to decrease formation of a toxic protein complex containing RBM17 (Supplementary Fig. 16 ). Nevertheless, we cannot rule out the possibility that ATXN1-CIC-containing complex is also neuroprotective. We found that glutamine-expanded ATXN1 preferentially forms a complex with RBM17, whereas wild-type ATXN1 is found in the CIC-containing complex. Therefore, when one allele is glutamine-expanded, the levels of wild-type ATXN1 decrease and less wild-type ATXN1-CIC complexes can be formed. Our previous findings 23 that the repressive activity of CIC is more robust in the presence of wild-type ATXN1 than with glutamine-expanded ATXN1 argue that a net effect of decreased ATXN1-CIC activity and the decreased co-repressive activity owing to mutant ATXN1 might also contribute to SCA1 pathogenesis. Although these data indicate that ATXN1-CIC complexes cause a partial loss of wild-type ATXN1 function, we cannot exclude the possibility that a mutant ATXN1-CIC complex might actively contribute to SCA1 pathogenesis. We propose a two-pronged model of SCA1 neurodegeneration in which augmented function of a particular stable endogenous protein complex is combined with a simultaneous loss of function of other, stable endogenous protein complexes (Fig. 6c ).
This dual model may apply equally well to several other dominant neurodegenerative diseases caused by a gain-of-function mutational mechanism including other polyglutamine diseases [31] [32] [33] [34] [35] [36] [37] [38] , prion disease 39, 40 and Alzheimer's disease 41, 42 . Relatively recent work indicates that some of the polyglutamine diseases might also involve a partial loss of function of the wild-type host proteins [31] [32] [33] [34] [35] [36] [37] [38] . However, the clear mechanism by which polyglutamine expansion causes both toxic gain of function and simultaneously loss of function of the diseasecausing protein has not been clarified so far. In Huntington's disease, loss of mouse huntingtin (Htt) function intensifies neurodegeneration in transgenic models bearing the expanded protein [32] [33] [34] . Htt regulates REST (also called NRSF) activity differentially depending on whether it is wild type or polyglutamine-expanded 37 . Although the mechanism has not been fully described, the mutant Htt may exert a dominant deleterious effect on REST activity by losing its ability to sequester REST in the cytoplasm. In the dominantly inherited prion diseases, mutant prion proteins cause toxicity mainly through a toxic gain-of-function mechanism by interfering with essential cellular processes and activating cell death pathways 40 . In addition, some pathogenic mutations might also impair certain physiological functions of the normal host protein, contributing to disease by loss of a neuroprotective function of wild-type prion protein 39, 40 . In the case of Alzheimer's disease, increased production and aggregation of the amyloid beta peptide by Alzheimer'sdisease-related presenilin mutations is widely accepted to have a key role in Alzheimer's disease through a dominant gain-of-function mechanism 42 . However, recent work demonstrates that inactivation of presenilin in the adult cerebral cortex causes progressive memory loss and neurodegeneration that strikingly resemble Alzheimer's disease 41 . Whether presenilin mutations contribute to Alzheimer's disease through a gain-and/or a loss-of-function mechanism is not yet understood, but our finding that the interactions of the mutant protein with its usual partners are differentially affected by the polyglutamine expansion offers a mechanistic explanation for how mutant proteins can gain and lose function simultaneously.
METHODS SUMMARY
Yeast two-hybrid mating type screens 43 of human open reading frame (ORF) clones were performed using the hORFeome v1.1, as described 20 . The co-affinity purification and co-immunoprecipitation experiments were performed using cell lysates or mouse cerebellar extracts, as described 20, 23 . Gel-filtration chromatography was performed using soluble extracts from about 20-week-old mouse cerebellum or cells as described 23 . Drosophila SCA1 model and dRBM17 mutant flies were used to test a genetic interaction between the two proteins. The dRBM17 J23 allele is a strong hypomorphic or amorphic allele of dRBM17 whereas Df(2Lh)D1 is a deficiency that spans the dRBM17 region 28 . Processing and image acquisition of Drosophila eye for scanning electron microscopy were performed as described 23 . Immunofluorescence staining and rotarod analysis were performed as described 24, 25 . 
